Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-Finding Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT04169711 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.

NCT NCT04169711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04169711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-Finding Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
Arrowhead Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
August 17, 2020
Completion date
July 22, 2022
Enrollment
26 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma